The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The aim of the study was to conduct a multicenter randomized double-blinded placebo-controlled clinical study to evaluate the efficacy of a generic form of escitalopram in treating major depressive disorder (MDD). A total of 390 MDD patients admitted to hospitals in six cities in China were randomized to receive the generic version of escitalopram, the proprietary form of escitalopram (Lexapro) or placebo. During the 8-week treatment, the Hamilton rating scale for depression-17 (HAM-D 17), Hamilton Anxiety Rating Scale (HAMA), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions scale (CGI), current visual analogue scale pain levels (VAS-P1) and Sheehan Disability Scale (SDS) assessments were performed at week 0, 1, 2, 4, 6 and 8 to evaluate treatment responses. HAM-D 17, MADRS, HAMA and CGI-S levels of patients who received escitalopram or Lexapro decreased steadily during 8 weeks’ treatment, whereas the placebo group showed a relatively smaller reduction of these levels (P < 0.001). SDS and VAS-P1 both decreased after treatment with generic escitalopram or proprietary escitalopram Lexapro. Our results indicated that both the generic escitalopram and proprietary escitalopram Lexapro had potent efficacy in treating MDD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies demonstrate that Escitalopram, one of the most selective SSRI, has great efficacy in relieving the symptoms of MDD in China.8”
Citations
Cites
The clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,759
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467 · cited 2×
“, 2007) and Sheehan Disability Scale (SDS) assessments (Sheehan and Sheehan, 2008).”
BackgroundMethodA one-item question with a Likert or Visual Analog Scale adequately measured current anxiety
Davey, H. M., Barratt, A. L., Butow, P. N., & Deeks, J. J. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.07.015 · Cited by 366
Major Depressive Disorder Treatment Guidelines in America and Europe
Davidson, J. R. T. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9058se1c.04gry · Cited by 344 · cited 1×
“Current antidepressants for MDD have not achieved optimal outcomes (Davidson, 2010; Gelenberg, 2010), and the recurrence rate is still high among patients.”
BackgroundMüller, M. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00120-9 · Cited by 282
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Cited by
Huo, T., Zhao, X., Cheng, Z., Wei, J., Zhu, M., Dou, X., & Jiao, N. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.021 · Cited by 110
Rapid metal-free reduction of aromatic nitro compounds to aromatic amines in MeOH/H2O with B2pin2
Wang, W., Liu, Z., Liu, M., Ai, Y., Fu, Z., & Qin, C. (2024) · Tetrahedron · doi:10.1016/j.tet.2024.134130 · Cited by 10
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s491768 · Cited by 3
Li, Z., Wu, T., Xiong, Y.-T., Zhang, X., Bao, Y., Guo, L.-B., Bao-jie, H., Li, S., Wang, Y., Lü, L., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1188175 · Cited by 4
Self-citation
Metadata
- Authors
- Wang, X., Fan, Y., Li, G., & Li, H.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Li, Guanjun
- Li, Huafang
- Venue
- International Clinical Psychopharmacology
- Published
- 2021-05
- Volume
- 36
- Issue
- 3
- Pages
- 133-139
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W3145695501
- Cited by
- 4
- References
- 20
- Citations by year
- 2024: 2 · 2023: 2
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, major depressive disorder, generic drugs, antidepressant efficacy, selective serotonin reuptake inhibitors, anxiety symptoms, disability, pain, hospital outpatients
- MeSH terms
- Escitalopram, China, Major Depressive Disorder, Double-Blind Method, Humans, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. https://app.cochat.ai/papers/10.1097/yic.0000000000000350
- The paper
- Wang, X., Fan, Y., Li, G., & Li, H. (2021). The efficacy of escitalopram in major depressive disorder: a multicenter randomized, placebo-controlled double-blind study. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000350
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.